AstraZeneca Partners with Oracle for AI-Driven Clinical Trials
The non-binding agreement will test AI tools to find eligible patients earlier and speed evidence generation across trial and care workflows.
- On Tuesday, October 20, 2026, AstraZeneca announced a collaboration with Oracle to use artificial intelligence and real-world data to accelerate clinical research and improve patient recruitment for trials.
- Patient recruitment remains a primary challenge in clinical research, as delayed enrollment extends development timelines and increases costs, prompting AstraZeneca to address past trial design failures.
- The first project will support hypertension research in Abu Dhabi through a partnership with healthcare firm M42. Chief Executive Officer Pascal Soriot said the collaboration brings "leaders in healthcare and AI together at a global scale."
- Combining AstraZeneca's drug development expertise with Oracle's cloud and analytics capabilities, the partnership aims to help clinicians identify eligible patients sooner. Seema Verma, executive vice president of Oracle Health and Life Sciences, said progress depends on "shortening the distance between scientific insight and the decisions clinicians make every day."
- AstraZeneca intends to expand its medicine portfolio, targeting over $80 billion in annual revenue by 2030. Chief Digital, Data and AI Officer Anne-Claire Gerbaldi noted the technology aims to address care gaps where patients face long diagnostic journeys.
11 Articles
11 Articles
Channel News Asia
AstraZeneca partners with Oracle for AI-driven clinical trials
Oct 20 : AstraZeneca said on Tuesday that it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research.• The collaboration will combine AstraZeneca's drug develo
AstraZeneca, Oracle to launch their first global AI program in Abu Dhabi: CEO
AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first programme set for Abu Dhabi in partnership with M42. CNBC's Dan Murphy speaks to AstraZeneca's CEO Pascal Soriot live from the sidelines of the Future Health Summit in Abu Dhabi.
Waterloo Cedar Falls Courier
Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation
Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to help improve patient care
Astrazinica, Tuesday, announced that it was cooperating with Oracle to use artificial intelligence and factual data to identify appropriate patients to participate in, inter alia, clinical trials and control of safety indicators, as the pharmaceutical manufacturer sought to upgrade clinical research.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
